Replies to post #608065 on NorthWest Biotherapeutics Inc (NWBO)

[10baggerz]

UK approval would change literally EVERYTHING for NWBO and make it EXPONENTIALLY harder (more expensive) for shorts to manipulate the price.
1. Everyone with GBM will immediately demand it.
2. Every medical professional will immediately demand it.
3. Every GBM organization will talk about it.
4. Every reputable news organization will cover it.
5. AF et. al Will immediately lose their most of their ability to cast doubt on approvals
6. The chances of FDA approval will go up exponentially (don’t believe anyone that tells you that they don’t care what the MHRA does).
7. GBM patients and advocates in the US will immediately create buzz about the lack of approval in the US (and elsewhere)
8. GBM patients with the financial means from all over the world to get treatment in the UK.
9. Every BP will take notice of the first new treatment for GBM in 20 years which just so happens to be extremely effective in combination with other treatments.
10. Revenues would be almost immediate and would be substantial even with just UK GBM patients alone.
11. Both the need for and the amount of dilution would be greatly reduced and even eliminate.
12. Short squeezes happen and if NWBO has 10% of the naked shorts that many estimate, the approval squeeze could be violent.
13. The risk of insolvency would be dramatically reduced.
14. The chances of uplifting would be immediately and exponentially increased.
15. Combo trials would immediately be in massive demand.
The list goes on and on!!!